Small molecule ACK1 inhibitor (R)-9b ... - Advanced Prostate...

Advanced Prostate Cancer

22,016 members27,617 posts

Small molecule ACK1 inhibitor (R)-9b - third generation AR receptor - clinical trial I in 2023

2 Replies

Technogenesys will start a trial in 2023, be prepared:

Thus,, there is an acute need for next generation of inhibitor that can overcome Enzalutamide and Abiraterone resistance. We have identified (R)-9b as a `third generation' of AR-antagonist, which has ability to overcome Enzalutamide and abiraterone-resistant prostate cancer.

Read more about...
2 Replies
GP24 profile image
GP24

More details here: technogenesys.com/ack1-inhi...

Fennelli profile image
Fennelli

My husband was on Enzalutemide for eleven months before treatment failed. Initially PSA halved but out of control blood pressure requiring three different medications to treat, and a very noticeable brain fog were the worst side effects - he had real difficulty in thinking. Fortunately since no longer taking the drug, his mental acuity has returned to normal. Muscle tone was also dramatically affected by Enzalutemide. But, he has been told that Enzalutemide works well for many patients but just does not suit everyone. Now on Lutetium 177 and very happy with the results to date. Good luck to all.

Not what you're looking for?

You may also like...

Quercetin & AR-V7.

New study below [1]. A common form of resistance to Xtandi & Zytiga is the emergence of androgen...

Abiraterone vs Enzalutamide + Radiation

I would like to solicit the valued opinion of members of the HU community regarding the potential...

Abiraterone and Enzalutamide Raise Metabolic, Cardiovascular Adverse Event Risks

Abiraterone was significantly associated with an 84% and 37% increased risk for a major or minor...

Teddyb2

Does anyone have any experience of abiraterone or enzalutamide?

BAT therapy - NIH article

Efficacy and safety of bipolar androgen therapy in castration-resistant prostate cancer following...